Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice

Tiantian Liu,1,2 Xiaomeng Tang,1,2 Yun Cui,1,3 Xi Xiong,1,2,3 Yaya Xu,4 Shaohua Hu,5 Shuyun Feng,1,2 Lujing Shao,1,2 Yuqian Ren,1,2,3 Huijie Miao,1,2,3 Hong Zhang,5 Xiaodong Zhu,4 Yucai Zhang,1,2,3 and Chunxia Wang1,2,3,6

1Department of Critical Care Medicine, Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine, 200062 Shanghai, China
2Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Jiao Tong University School of Medicine, 200062 Shanghai, China
3Institute of Pediatric Critical Care, Shanghai Jiao Tong University, 200062 Shanghai, China
4Department of Pediatric Critical Care Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 200092 Shanghai, China
5Department of Clinical Laboratory, Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine, 200062 Shanghai, China
6Clinical Research Unit, Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine, 200062 Shanghai, China

Correspondence should be addressed to Yucai Zhang; zyucai2018@163.com and Chunxia Wang; karenx0465@163.com

Received 3 April 2022; Revised 31 May 2022; Accepted 7 June 2022; Published 6 July 2022

Academic Editor: Ramoji Kosuru

Copyright © 2022 Tiantian Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis is extremely heterogeneous pathology characterized by complex metabolic changes. Fibroblast growth factor 19 (FGF19) is a well-known intestine-derived inhibitor of bile acid biosynthesis. However, it is largely unknown about the roles of FGF19 in improving sepsis-associated metabolic disorder and organ injury. In the present study, mice were intravenously injected recombinant human FGF19 daily for 7 days followed by lipopolysaccharide (LPS) administration. At 24 hours after LPS stimuli, sera were collected for metabolomic analysis. Ingenuity pathway analysis (IPA) network based on differential metabolites (DMs) was conducted. Here, metabolomic analysis revealed that FGF19 pretreatment reversed the increase of LPS-induced fatty acids. IPA network indicated that altered linoleic acid (LA) and gamma-linolenic acid (GLA) were involved in the regulation of oxidative stress and mitochondrial function and were closely related to reactive oxygen species (ROS) generation. Further investigation proved that FGF19 pretreatment decreased serum malondialdehyde (MDA) levels and increased serum catalase (CAT) levels. In livers, FGF19 suppressed the expression of inducible NO synthase (iNOS) and enhanced the expression of nuclear factor erythroid 2-related factor 2 (NRF2) and hemeoxygenase-1 (HO-1). Finally, FGF19 pretreatment protected mice against LPS-induced liver, ileum, and kidney injury. Taken together, FGF19 alleviates LPS-induced organ injury associated with improved serum LA and GLA levels and oxidative stress, suggesting that FGF19 might be a promising target for metabolic therapy for sepsis.

1. Introduction

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. Sepsis-induced dysregulated lipid metabolism is characterized by decreased serum high-density lipoprotein, total cholesterol, and low-density lipoprotein and elevated triacylglycerols [2]. As the main site for lipid metabolism, the liver suffers from excess free fatty acids (FFAs) resulting in lipotoxicity and sepsis-associated liver injury (SALI) [3]. Therefore, we speculated that improving the lipid metabolic disorder could be a novel therapeutic strategy for SALI.
Fibroblast growth factor 19 (FGF19), as an intestine-derived hormone, enters the liver through the portal vein and suppresses bile acid (BA) and FA synthesis in hepatocytes [4–6]. Given its roles in metabolic regulation, FGF19 is a potential molecular target for type 2 diabetes and non-alcoholic fatty liver disease [7, 8]. Recently, FGF19 analogues or mimics are entering phase 3 clinical research in non-alcoholic steatohepatitis (NASH) [9]. Mechanically, FGF19 binds to FGF receptor 4 (FGFR4) to inhibit cholesterol 7α-hydroxylase activity resulting in BA synthesis suppression, and mammalian target of rapamycin complex 1 (mTORC1) is an essential mediator of FGF19 involved in metabolic effects [10, 11]. Moreover, FGF19 promotes FA oxidation and improves mitochondrial dysfunction in skeletal muscle partially through AMP-activated protein kinase (AMPK) signaling pathway [12, 13]. Importantly, recent study proved that lipopolysaccharide (LPS) inhibited the expression of FGFR4 in the livers of mice [14], and our previous study elucidated the association between serum FGF19 level and sepsis-associated gastrointestinal dysfunction [15]. Therefore, we speculated that FGF19 could be a key regulator of metabolism homeostasis and plays a protective role in sepsis-associated metabolic disorder and organ injury.

Metabolomics has been paid more attention in critically ill due to its comprehensive analysis for metabolic alteration [16]. Serum or plasma is usually used for metabolic profile analysis to identify metabolic biomarkers [17–19]. Besides, machine learning method based on integrated pathway analysis (IPA) generating metabolites-related regulatory networks provides a more effective and intuitive way to acquire potential pathological mechanisms [20–22]. In the present study, we aimed to explore the role of FGF19 in LPS-induced serum metabolic profile disturbance in mice using targeted liquid chromatography coupled with mass spectrometry (LC-MS) (Figure 1).

2. Materials and Methods

2.1. Animal. A total of 48 male C57BL/6J mice (8–10 weeks old) were purchased from Shanghai Southern Model Animal Experimental Center (Shanghai, China). Mice were caged on a 12-h light/dark cycle at 25°C and were allowed free access to tap water and a standard rodent chow ad libitum. Mice were randomly divided into four groups including control, LPS, only FGF19 treatment (FGF19), and FGF19 pretreatment followed by LPS administration (FGF19 + LPS). To construct endotoxemia model to mimic sepsis and sepsis-associated organ dysfunction, mice were intraperitoneally injected with LPS (5 mg/kg, E. coli 0111: B4, Sigma-Aldrich Co.) for 24 h [23]. Recombinant human FGF19 (Novoprotein, China) was intravenously injected via tail vein at a dose of 0.1 mg/kg body weight daily for 7 days before LPS treatment. The management and experimental care of mice were conducted in accordance with the protocol that was approved by the Ethics Committee of Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China).

Mice were sacrificed at 24 h after LPS administration. Blood samples were collected and centrifuged at 3000 rpm for 15 min to separate serum. The serum samples from a batch of animals (6 mice per group) were sent for metabolomic experiments. The liver, ileum, kidney tissues, and serum samples of the other batch of animals (6 mice per group) were collected and performed to molecular biological experiments. In addition, liver tissues were flash frozen in liquid nitrogen for further analysis.

2.2. Sample Preparation and LC/MS Analysis. Metabolomic analysis was conducted using Q300 Kit (Metabo-Profile Biotechnology, Shanghai, China). Due to quality control (QC) test, 20 QC-passed serum samples (5 mice per group) were further analyzed by targeted metabolomics. Detailed methods and statistical analysis for metabolomic data are available in the Supplementary Materials (available here).

2.3. Integrated Analysis of Metabolomics. IPA software (IPA China, provided by Shanghai Jiao Tong University School of Medicine) was used to analyze differential metabolites (DMs) based on metabolomics to construct molecular interaction network models (comparison analysis).

2.4. Histological Examination. Liver, ileum, and kidney tissues were harvested and fixed in 4% paraformaldehyde overnight and next embedded in paraffin. 4-μm thickness tissue sections were stained with hematoxylin and eosin (H&E), and images were captured randomly under light microscopy. Liver, ileum, and kidney injury scores were determined as described before [24–26]. All injury assessments were performed by two observers who were unaware of the treatment. The final score was expressed as an average grade.

2.5. Liver Immunohistochemical (IHC) and Immunofluorescence (IF) Staining. Liver tissue sections were incubated with primary and then secondary antibodies following the routine protocols of IHC and IF. For IHC staining, anti-inducible NO synthase (iNOS) antibody was purchased from Abcam (ab3523, UK). For IF staining, anti-hemeoxygenase-1 (HO-1) antibody was purchased from CST (#43966, USA). Horse radish peroxidase-conjugated or fluorescence-conjugated secondary antibody (Rabbit) was purchased from ebioScience (Shanghai, China).

2.6. Biochemical Analysis for Oxidative Stress. Serum levels of catalase (CAT) and malondialdehyde (MDA) were measured using corresponding commercial assay kits according to the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, China).

2.7. Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR). The total RNA from liver tissue was prepared with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). qPCR was performed on an ABI 7500 system (Applied Biosystem, Foster, CA, USA). The relative mRNA expressions for targeted genes were normalized by reference gene Gapdh and were calculated by 2^{−ΔΔCT} method. The sequences of primers used for RT-qPCR were showed in Supplementary Materials.
2.8. Western Blotting. Liver tissues were homogenized in RIPA lysis buffer (Beyotime Biotechnology). The following antibodies were used in this study: anti-β-Actin (1: 1000, #3700, CST), anti-Cytochrome c (1 : 1000, #3700, CST), anti-Cleaved Caspase-3 (1 : 1000, #9664, CST), anti-HO-1 (1 : 1000, #10701, Proteintech), anti-NRF2 (1 : 1000, #16396, Proteintech), and the secondary anti-Rabbit antibody (eBioscience, Shanghai, China). Relative protein levels were obtained by normalized to β-Actin. The intensities of protein band were analyzed by ImageJ software.

2.9. Statistical Analysis. Normally distributed continuous variables are presented as mean ± SEM, and Student t -test was used to compare the difference between two groups. GraphPad Prism version 8 (GraphPad Software, La Jolla, CA, USA) was used for comparison analysis. P < 0.05 was considered statistically significant.

3. Results

3.1. Serum Overall Metabolic Profiles in Mice. There were 207 DMs in sera among four groups, which were divided into 16 classes, including carbohydrates, amino acids, organic acids, FAs, short-chain fatty acids (SCFAs), carnitines, BAs, nucleotides, phenols, peptides, benzenoids, pyridines, phenylpropanoic acids, benzoic acids, indoles, and phenylpropanoids. Among them, carbohydrates, amino acids, organic acids, and FAs were the major metabolite components. LPS remarkably increased the levels of FAs, and FGF19 reversed LPS-induced effect in mice (Figures 2(a) and 2(b)). Furthermore, FGF19 decreased the mRNA levels of fatty acid synthase (Fasn), ATP-citrate lyase (Acly), and increased the mRNA levels of fatty acid transport protein 1 (Fatp1) and carnitine palmitoyltransferase 1α (Cpt1α) in the livers in response to LPS (Figure S1).
However, there were not significantly differences in serum carbohydrates levels, amino acids levels, organic acids levels, or others in the FGF19 + LPS group compared with LPS group (Figures 2(c)–2(f)).

3.2. Multidimensional Statistics Analysis of Serum Metabolic Profile. In the PCA model, QC samples were successfully separated from the tested samples and clustered together (Figure 3(a)). The metabolites in sera of mice in the LPS group or FGF19 + LPS group were well separated from the control or LPS group in the 2D PCA plot, respectively (Figures 3(b) and 3(c)). However, there was no significantly separation between FGF19 group and control group (Figure 3(d)). Moreover, OPLS-DA score plots displayed similar results as shown in the 2D PCA plot (Figures 3(e) and 3(g)). Further permutation test proved that the OPLS-DA model have good robustness without overfitting (Figures 3(f) and 3(h)).
Figure 3: Continued.
Figure 3: PCA scatter plot and OPLS-DA analysis of metabolite profile. Mice were divided into four groups including control, LPS, only FGF19 treatment (FGF19), and pretreatment with FGF19 followed by LPS administration (FGF19+LPS) \((n = 5)\). (a) Score plot with aggregated quality control (QC) samples, (b–d) 2D PCA plot of LPS vs. control group (b), FGF19+LPS vs. LPS group (c), FGF19 vs. control group (d). (e–h) OPLS-DA score scatter plots and permutation test of OPLS-DA model of LPS vs. control group (e, f) and FGF19+LPS vs. LPS group (g, h). The abscissa indicates the displacement retention of the permutation test, and the ordinate indicates the value of \(R^2_Y\) or \(Q^2\). The green dot indicates the \(R^2_Y\) value obtained by the displacement test, the blue square indicates the \(Q^2\) value obtained by the permutation test, and the two dotted lines indicate the regression lines of \(R^2_Y\) and \(Q^2\), respectively. The point where the displacement retention is 1 is \(R^2_Y\) and \(Q^2\) of the original model.

Figure 4: Continued.
2-phenylglycine
5-aminolevulinic acid
5-hydroxylysine
Acctylglycine
Alpha-aminobutric acid
Beta-alanine
Creatine
Histidine
Homocitrulline
Histamine
Methionine
Methionine sulfoxide
Methylcysteine
N-acetylglutamine
N-acetylserine
Phenacetylglutamine
Proline
Serine
Tyrosine
Mandelic acid
Phenylpyruvic acid
CDCA
Glutaric acid
GLucaric acid
Glucose
Glucose 6-phosphate
Glyceric acid
N-acetyl-D-glucosamine
N-acetyllactosaminic acid
Rhamnose
Adipoylcarnitine
Decanoylcarnitine C10
Dodocanoylcarnitine
Glutarylcarnitine
Linoleoylcarnitine
Oleoylcarnitine
Palmitoylcarnitine
Tetradecanoylcarnitine
10Z-heptadecenoic acid
10Z-Nonadecenoic acid
2, 2-Dimethyladipic acid
9E-tetradecenoic acid
Adrenic acid
Arachidonic acid
Citracionic acid
DHA
Dihomo-gamma-linolenic acid
Dodecanonic acid
Gamma-linolenic acid
Heptadecanoic acid
Linolenic acid
Linoleic acid
Methylglutaric acid
Myristic acid
Myristoleic acid
Olive oil
Palmitic acid
Pentadecanoic acid
Pentadecanoic acid
Sebacic acid
Tridecanonic acid
Indole-3-propionic acid
Indolylacetic acid
2-furoic acid
2-hydroxybutyric acid
3-methyl-2-oxopentanoic acid
Alpha-hydroxyisobutyric acid
Fumaric acid
Glycolic acid
Maleic acid
Malic acid
Malonic acid
Oxoglutaric acid
Pyruvic acid
Shikimic acid
2-phenoxypropionic acid
Hydroxyisovaleric acid
Phenylactic acid
Cinnamic acid
3-hydroxyisovaleric acid

(c) Figure 4: Continued.
3.3. Differential Metabolites and Potential Biomarkers Screened from Serum Metabolomics in Mice. According to variable importance in projection (VIP) >1 and $P < 0.05$, based on OPLS-DA multivariate data analysis and univariate statistics, a total of 82 DMs were found in the LPS group compared with control group, including 58 upregulated metabolites and 24 downregulated metabolites (Figure 4(a)). There were 33 DMs in the FGF19 + LPS group compared with LPS group, including 6 upregulated metabolites and 27 downregulated metabolites (Figure 4(b)). There were 25 DMs appeared in both LPS vs. control and FGF19 + LPS vs. LPS group at the same time. Potential metabolites affected by FGF19 in response to LPS included 6 kinds of amino acids (histidine, β-alanine, methylcysteine, α-amino-butyric acid, acetylglucose, and N-acetylglutamine), 12 kinds of fatty acids (sebacic acid, tridecanoic acid, myristoleic acid, myristic acid, pentadecanoic acid, gamma-linolenic acid, linoleic acid, linoelaidic acid, dihomo-gamma-linolenic acid, DHA, oleic acid, and petroselinic acid), 1 kind of carbohydrate (N-acetyl-D-glucosamine), 4 kinds of carnitines (linoleyl carnitine, dodecanoylcarnitine, palmitoylcarnitine, and tetradecanoylcarnitine), and 2 kinds of organic acids (glycolic acid and pyruvic acid). Among these metabolites, amino acids, FAs, carbohydrate, and carnitines were increased, while organic acids were decreased in response to LPS. Intriguingly, FGF19 almost totally reversed these changed induced by LPS (Figures 4(c)–4(e)).

3.4. Metabolic Enrichment and Pathway Analysis of Differential Metabolites. Pathway enrichment analysis
Oxidative Medicine and Cellular Longevity

Figure 5: Continued.
revealed that α-linolenic acid (α-LA) and linoleic acid (LA) metabolism were significantly enriched in DMs in either LPS group compared with control group or FGF19 + LPS group compared with LPS group (Figures 5(a) and 5(b)). Detailed pathway analysis indicated that biosynthesis of USFAs was the potential pathway contributed to FGF19-mediated changes of metabolites in response to LPS stimuli (Figures 5(c) and 5(d)). Furthermore, LA, gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), and DHA were significantly decreased in sera of FGF19-pretreated mice (Figures 5(e)–5(h)).

**3.5. Network and Comparison Analysis in Integrated Pathway Analysis.** The 82 DMs in response to LPS or 33 DMs related to FGF19 pretreatment in response to LPS were submitted to IPA. Network function analysis revealed that 82 DMs were involved in "immunological disease, inflammatory disease, and inflammatory response" with a score of 48, and 33 DMs were mainly responsible for "cellular compromise, lipid metabolism, and small molecule biochemistry" with a score of 33 (Figures 6(a) and 6(b)). Interestingly, we found LA was related to NADPH oxidase (NOS) and cytochrome-c oxidase (COX) in the LPS group, while GLA was relevant to superoxide and COX in the FGF19 + LPS group. Next comparison analysis demonstrated that FGF19 pretreatment inhibited LPS-induced necrosis and reactive oxygen species (ROS) production (Figure 6(c)). Moreover, further analysis based on comparison analysis also enclosed that LA and GLA were involved in generation of ROS (Figures 6(d) and 6(e)).

**3.6. FGF19 Pretreatment Alleviates LPS-Induced Organ Injury.** Histological analysis indicated that FGF19 pretreatment partially ameliorated LPS-induced liver, ileum, and kidney injury, displaying significantly lower injury scores (Figure 7(a)). Furthermore, FGF19 pretreatment significantly inhibited LPS-induced expression of Cleaved Caspase-3 and Cytochrome c in the liver (Figure 7(b)).

**3.7. FGF19 Pretreatment Improves LPS-Induced Oxidative Stress.** IPA results suggested that FGF19 pretreatment ameliorated LPS-induced organ injury and inflammatory stress.
Figure 6: Continued.
response, which might be related to generation of ROS. Thus far, we run a series of validation tests to verify relationship of FGF19 and oxidative stress. Interestingly, serum MDA level was decreased, and serum CAT level was increased in FGF19-pretreated mice (Figure 8(a)). The mRNA levels of glutathione peroxidase 1 (Gpx1) and Cat in livers were significantly higher in mice pretreated with FGF19 compared with LPS-treated mice, but not superoxide dismutase (Sod1 and Sod2) (Figure 8(b)). Consistently, both the mRNA and protein levels of iNOS were significantly decreased in the FGF19-pretreated group compared with LPS group (Figures 8(b) and 8(c)). Furthermore, FGF19 pretreatment promoted the LPS-suppressed expression of NRF2 and HO-1 in the livers (Figures 8(b) and 8(d)–8(f)).
4. Discussion

Metabolic disturbance is a critical characteristic of sepsis and also is a potential entry for developing novel therapeutic strategy for sepsis. In the present study, we found that FGF19 pretreatment attenuates LPS-induced organ injury associated with LA/GLA-ROS generation-NRF2/HO-1 pathway (Figure 9). To the best of our knowledge, it is the first...
Figure 8: Continued.
report about FGF19 regulating serum LA/GLA levels involved in sepsis-associated organ injury, which gives a new sight into the metabolic strategy for sepsis treatment.

Metabolic response to LPS in healthy people is concordant with that of community-acquired sepsis survivor [27]. LPS-induced mice model was reported to be used for investigating the potential metabolites involved in improving organ injury [28]. As described in our previous studies [29, 30], LPS-induced mice model was used in this study. We previously reported that serum FGF19 level was decreased in patients with sepsis-associated gastrointestinal dysfunction [15]. The gut barrier failure leads to increased levels of inflammatory factors and absorption of LPS and decreased bacteria clearance, aggravating SALI [31]. Moreover, FGF19 regulates FA metabolism for treatment of NASH [32]. In this study, we revealed that FGF19 partially suppresses LPS-induced FA synthesis and promotes FA transport and β-oxidation in livers and influences FAs levels including oleic acid, LA, and GLA in serum. This study gave a new insight into FGF19-mediated changes of FA profiles in response to LPS. Considering the characteristic of intestine-derived, FGF19 could be a potential therapeutic target for sepsis from the view of FA regulation.

Through analyzing the DMs between LPS vs. control group and LPS vs. FGF19+LPS group, 25 DMs were screened and potentially involved in the protective roles of FGF19 in LPS-induced metabolic disorders. Among these, 12 fatty acids were involved. For example, myristic acid is a saturated FA, whose increment might be related to the alteration of lipid metabolism and energy production in sepsis [33, 34]. In a cohort of septic patients and patients with systemic inflammatory response syndrome (SIRS), serum myristic acid was significantly higher in sepsis and SIRS group, which indicates myristic acid should be considered as a new candidate marker for sepsis [35]. In summary, FGF19 pretreatment mainly improved LPS-induced lipid metabolism, indicating FGF19 might be closely associated with improved metabolic disturbance of sepsis. Aldafermin (NGM282), an FGF19 engineered analogue, is mainly applied in clinical trial including NASH [36] and primary sclerosing cholangitis [37]. Currently, NGM282 is applied in phase 2 clinical trials in NASH showing favorable clinical effect on reducing liver fat and improving fibrosis (ClinicalTrials.gov, Number: NCT02443116) [38]. In atherosclerosis, both FGF19 and NGM282 regulated cholesterol homeostasis and improved hepatic steatosis in db/db mice [6]. In the future, the potential therapeutic values of NGM282 or other FGF19 analogue in sepsis should be conducted in a well-designed clinical trial.

Our detailed pathway analysis results showed that FGF19 pretreatment suppressed USFA biosynthesis and LA and GLA were involved. Peritoneal fluid metabolomics or serum metabolomics revealed that LA level was increased in rodent treated by LPS, and biosynthesis of USFA was influenced [39, 40]. In agreement with these previous study, LPS increased LA, GLA, DGLA, and DHA. Instead, FGF19 pretreatment reversed the effect. LA is converted to arachidonic acid (AA) via GLA and DGLA, and LA is converted to DHA via α-LA [41, 42]. The levels of AA were increased by a two-fold in patients with severe sepsis [43]. Moreover, LPS-induced LA and AA led to increased FFAs and prostaglandin E2 in serum resulting in organ injury [44]. We suspected that LPS-induced LA metabolism disturbance is earlier than organ injury. Accumulated evidences indicated that USFA are substrates for the synthesis of multiple molecules that are active in inflammatory response [45–48].
Decreased Omega 6/Omega 3 FAs were proved to attenuate ethanol-induced liver injury [49]. So, we suspected that FGF19 improves LPS-induced organ injury mainly via downregulating LA metabolism. However, the detailed mechanisms underlying FGF19 affecting LA and GLA levels need further investigation in the future. Serum metabolomics could be affected by diet and gut microbiome, and it is limited to analyze metabolites produced endogenously [50]. So, the role of supplement to specific microbial metabolites and analysis of tissue metabolomics need further investigation in the future.

Imbalance of oxygen metabolism was manifested as increased oxygen demand and aerobic anaerobic respiration in a sepsis model in rats [40]. Metabolomic data indicated that FGF19 improved the level of pyruvic acid, suggesting FGF19 possibly improves LPS-induced mitochondrial dysfunction. FFAs overload results in incomplete oxidation in the mitochondria, peroxisomes, and microsomes, leading to the generation of ROS [51, 52]. LA could produce more mitochondria-derived ROS than other FFAs [53]. In the present study, IPA network showed that FGF19-induced changes of LA and GLA levels were associated with ROS generation in response to LPS. Otherwise, FGF19 could protect oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/NRF2/HO-1 pathway [54]. In our study, FGF19 strongly induced NRF2 and HO-1 expression and suppressed iNOS expression in livers in response to LPS. Moreover, FGF19 increased serum Cat and hepatic Cat and Gpx1 mRNA expression. So, we supposed that FGF19 pretreatment might promote ROS clearance related to activating antioxidant enzymes.

Generally, the serum metabolomic profile through mice intraperitoneal-injected LPS with or without FGF19 pretreatment, IPA analysis, and our further validation tests revealed FGF19 improved LPS-induced lipid metabolic disorder and organ injury, which was associated with LA/GLA-generation of ROS pathway. However, the present study also has several limitations. The sample size for serum metabolomic analysis (n = 5) was small. LPS-induced mice model was only model used in this study. Thus, the conclusion should be further assessed in future studies. Moreover, serum LA and GLA levels in patients with sepsis could be paid more attention to monitor routinely, and potential relationship between serum LA and GLA levels and the outcome of sepsis should be further investigated in the future.

5. Conclusion

FGF19 pretreatment alleviates LPS-induced metabolic disorder and organ injury. Integrated pathway analysis implied that FGF19-reduced serum LA and GLA levels might be correlated to improving oxidative stress, and further experimental data confirmed that FGF19 activates NRF2/HO-1 pathway in response to LPS. So, FGF19 could be potential metabolic regulator during sepsis and therapeutic target for sepsis treatment.

**Abbreviations**

FGF19: Fibroblast growth factor 19  
LPS: Lipopolysaccharide  
IPA: Ingenuity pathway analysis  
DMs: Differentially metabolites  
LC-MS: Liquid chromatography coupled with mass spectrometry  
LA: Linoleic acids
Oxidative Medicine and Cellular Longevity

GLA: Gamma-linolenic acid
DGLA: Dihomo-gamma linolenic acid
ROS: Reactive oxygen species
MDA: Malondialdehyde
CAT: Catalase
iNOS: Inducible NO synthase
NRF2: Nuclear factor erythroid 2-related factor 2
HO-1: Hemeoxygenase-1
PCA: Principal component analysis
OPLS-DA: Orthogonal partial least squares discriminant analysis
VIP: Variable importance in projection
SMPDB: Pathway-associated metabolites sets
FFA: Free fatty acid
BA: Bile acid
SALI: Sepsis-associated liver injury
AMPK: AMP-activated protein kinase
NASH: Nonalcoholic steatohepatitis
FGFR4: FGF receptor 4
MDA: Malondialdehyde
ROS: Reactive oxygen species
DGLA: Dihomo-gamma linolenic acid
GLA: Gamma-linolenic acid

Data Availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval
The animal study was reviewed and approved by the Medical Ethics Review Committee of Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine.

Conflicts of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions
CW conceived the study. XZ, YZ, and CW obtained research findings. TL, XT, SF, XX, YR, LS, SH, and YX did experiments and analyzed the data. TL and CW drafted the manuscript. HM and YC reviewed the manuscript and contributed to discussion. XZ, YZ, and CW reviewed and edited the manuscript. YZ and CW are the guarantor of this work and takes responsibility for the integrity and the accuracy of this work. CW takes responsibility for the paper as a whole. All authors contributed to the work and approved it for publication.

Acknowledgments
This work is supported by the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20171928), Science and Technology Commission of Shanghai Municipality (18411951000), National Natural Science Foundation of China (82171729), and Natural Science Foundation of Shanghai (19ZR1442500). We would like to thank Metabo-Profile Biotechnology (Shanghai) for their technical support to this study.

Supplementary Materials
The Supplementary Material for this article can be found online. (Supplementary Materials)

References
[1] A. Rhodes, L. E. Evans, W. Alhazzani et al., “Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016,” Intensive Care Medicine, vol. 43, no. 3, pp. 304–377, 2017.
[2] A. Golucci, F. A. L. Marson, A. F. Ribeiro, and R. J. N. Nogueira, “Lipid profile associated with the systemic inflammatory response syndrome and sepsis in critically ill patients,” Nutrition, vol. 55-56, pp. 7–14, 2018.
[3] L. Van Wyngene, T. Vanderhaeghen, S. Timmermans et al., “Hepatic PPARα function and lipid metabolic pathways are dysregulated in polymicrobial sepsis,” EMBO Molecular Medicine, vol. 12, no. 2, article e11319, 2020.
[4] S. Bhatnagar, H. A. Damron, and F. B. Hillgartner, “Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis,” The Journal of Biological Chemistry, vol. 284, no. 15, pp. 10023–10033, 2009.
[5] T. Lan, D. A. Morgan, K. Rahmouni et al., “FGF19, FGF21, and an FGF19/β-Klotho-activating antibody act on the nervous system to regulate body weight and Glycemia,” Cell Metabolism, vol. 26, no. 5, pp. 709–718.e3, 2017.
[6] M. Zhou, R. M. Learned, S. J. Rossi, H. Tian, A. M. Depaoli, and L. Ling, “Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis[S],” Journal of Lipid Research, vol. 60, no. 3, pp. 550–565, 2019.
[7] S. Kir, S. A. Beddow, V. T. Samuel et al., “FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis,” Science, vol. 331, no. 6024, pp. 1621–1624, 2011.
[8] D. P. Sonne, “Mechanisms in endocrinology: FXR signalling: a novel target in metabolic diseases,” European Journal of Endocrinology, vol. 184, no. 5, pp. R193–r205, 2021.
[9] S. Talukdar and A. Kharitonenkov, “FGF19 and FGF21: In NASH we trust,” Molecular Metabolism, vol. 46, p. 101152, 2021.
[10] Z. Y. Wan, J. S. Tian, H. W. Tan et al., “Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells,” Hepatology, vol. 64, no. 4, pp. 1289–1301, 2016.
[11] Y. Wang, S. Gunwardena, F. Li et al., “An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis,” Nature Communications, vol. 11, no. 1, p. 3612, 2020.
[12] A. Guo, K. Li, H. C. Tian et al., "FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-1α pathway," *Journal of Cellular and Molecular Medicine*, vol. 25, no. 7, pp. 3585–3600, 2021.

[13] Y. N. Sun, Z. X. Yang, F. Z. Ren, and B. Fang, "FGF19 alleviates palmitate-induced atrophy in C2C12 cells by inhibiting mitochondrial overload and insulin resistance," *International Journal of Biological Macromolecules*, vol. 158, pp. 401–407, 2020.

[14] Y. Zhao, C. Meng, Y. Wang et al., "IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes," *American Journal of Physiology. Endocrinology and Metabolism*, vol. 310, no. 4, pp. E289–E300, 2016.

[15] X. Pang, "Clinical value of fibroblast growth factor 19 in predicting gastrointestinal dysfunction in children with sepsis," *Journal of Shanghai Jiao Tong University (Medical Science)*, vol. 40, pp. 1236–1242, 2020.

[16] M. Kiehnstrup, N. Nin, and M. Bauer, "Metabolism, metabolome, and metabolomics in intensive care: is it time to move beyond monitoring of glucose and lactate?", *American Journal of Respiratory and Critical Care Medicine*, vol. 187, no. 9, pp. 906-907, 2013.

[17] H. Jaurila, V. Koivukangas, M. Koskela et al., "1H NMR based metabolomics in human sepsis and healthy serum," *Metabolites*, vol. 10, no. 2, p. 70, 2020.

[18] J. Lee and D. Banerjee, "Metabolomics and the microbiome as biomarkers in sepsis," *Critical Care Clinics*, vol. 36, no. 1, pp. 105–113, 2020.

[19] J. Sun, J. Zhang, X. Wang et al., "Gut-liver crosstalk in sepsis-induced liver injury," *Critical Care*, vol. 24, no. 1, p. 614, 2020.

[20] E. Henriksson and B. Andersson, "FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human," *Frontiers in Endocrinology*, vol. 11, article 601349, 2020.

[21] A. M. Kauppi, A. Eden, I. Ziegler et al., "Metabolites in blood for prediction of bacteremic sepsis in the emergency room," *PLoS One*, vol. 11, no. 1, article e0147670, 2016.

[22] R. Zazula, M. Průcha, F. Pehal et al., "Kinetics of myristic acid following accidentally induced septic response," *Prague Medical Report*, vol. 120, no. 2-3, pp. 103–106, 2019.

[23] R. Zazula, M. Moravec, F. Pehal, T. Nejtek, M. Protů, and M. Müller, "Myristic acid serum levels and their significance for diagnosis of systemic inflammatory response, sepsis, and bacteræmia," *Journal of Personalized Medicine*, vol. 11, no. 4, p. 306, 2021.

[24] S. A. Harrison, M. E. Rinella, M. F. Abdelmalek et al., "NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial," *Lancet*, vol. 391, no. 10126, pp. 1174–1185, 2018.

[25] G. M. Hirschlhash, O. Chazouilleres, J. P. Drenth et al., "Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial," *Journal of Hepatology*, vol. 70, no. 3, pp. 483–493, 2019, PMID: 30414864.

[26] S. A. Harrison, G. Nef, C. D. Guy et al., "Efficacy and safety of Aldafarin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with non-alcoholic steatohepatitis," *Gastroenterology*, vol. 160, no. 1, pp. 219–231.e1, 2021.

[27] K. Kamisoglu, B. Haimovich, S. E. Calvano et al., "Human metabolic response to systemic inflammation: assessment of the concordance between experimental endotoxemia and clinical cases of sepsis/SIRS," *Critical Care*, vol. 19, no. 1, p. 71, 2015.

[28] Y. Ma, G. Liu, M. Tang, J. Fang, and H. Jiang, "Epigallocatechin Gallate can protect mice from acute stress induced by LPS while stabilizing gut microbes and serum metabolites levels," *Frontiers in Immunology*, vol. 12, p. 640305, 2021.

[29] L. Shao, X. Xiong, Y. Zhang et al., "IL-22 ameliorates LPS-induced acute liver injury by autophagy activation through ATF4-ATG7 signaling," *Cell Death & Disease*, vol. 11, no. 11, p. 970, 2020.

[30] X. Xiong, Y. Ren, Y. Cui, R. Li, C. Wang, and Y. Zhang, "Obez-ticolic acid protects mice against lipopolysaccharide-induced liver injury and inflammation," *Biomedicine & Pharmacotherapy*, vol. 96, pp. 1292–1298, 2017.

[31] J. Sun, J. Zhang, X. Wang et al., "Gut-liver crosstalk in sepsis-induced liver injury," *Critical Care*, vol. 24, no. 1, p. 614, 2020.

[32] E. Henriksson and B. Andersson, "FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human," *Frontiers in Endocrinology*, vol. 11, article 601349, 2020.

[33] A. M. Kauppi, A. Eden, I. Ziegler et al., "Metabolites in blood for prediction of bacteremic sepsis in the emergency room," *PLoS One*, vol. 11, no. 1, article e0147670, 2016.

[34] R. Zazula, M. Průcha, F. Pehal et al., "Kinetics of myristic acid following accidentally induced septic response," *Prague Medical Report*, vol. 120, no. 2-3, pp. 103–106, 2019.

[35] R. Zazula, M. Moravec, F. Pehal, T. Nejtek, M. Protů, and M. Müller, "Myristic acid serum levels and their significance for diagnosis of systemic inflammatory response, sepsis, and bacteræmia," *Journal of Personalized Medicine*, vol. 11, no. 4, p. 306, 2021.

[36] S. A. Harrison, M. E. Rinella, M. F. Abdelmalek et al., "NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial," *Lancet*, vol. 391, no. 10126, pp. 1174–1185, 2018.

[37] G. M. Hirschlhash, O. Chazouilleres, J. P. Drenth et al., "Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial," *Journal of Hepatology*, vol. 70, no. 3, pp. 483–493, 2019, PMID: 30414864.

[38] S. A. Harrison, G. Nef, C. D. Guy et al., "Efficacy and safety of Aldafarin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with non-alcoholic steatohepatitis," *Gastroenterology*, vol. 160, no. 1, pp. 219–231.e1, 2021.

[39] P. A. T. Pereira, C. S. Bitencourt, M. B. Reis et al., "Immunomodulatory activity of hyaluronidase is associated with metabolic adaptations during acute inflammation," *Inflammation Research*, vol. 69, no. 1, pp. 105–113, 2020.

[40] F. Ping, Y. Li, Y. Cao et al., "Metabolomics analysis of the development of sepsis and potential biomarkers of sepsis-induced acute kidney injury," *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 6628847, 22 pages, 2021.

[41] P. C. Calder, "Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients," *Brazilian Journal of Medical and Biological Research*, vol. 36, no. 4, pp. 433–446, 2003.
[42] M. J. Murray, G. Kanazi, K. Moukabary, H. D. Tazelaar, and S. J. Demichele, “Effects of eicosapentaenoic and γ-linolenic acids (dietary lipids) on pulmonary surfactant composition and function during porcine endotoxemia,” *Chest*, vol. 117, no. 6, pp. 1720–1727, 2000.

[43] M. Bruegel, U. Ludwig, A. Kleinhempel et al., “Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients,” *Critical Care Medicine*, vol. 40, no. 5, pp. 1478–1486, 2012.

[44] Y. J. Liu, H. Li, Y. Tian et al., “PCTR1 ameliorates lipopolysaccharide-induced acute inflammation and multiple organ damage via regulation of linoleic acid metabolism by promoting FADS1/FADS2/ELOV2 expression and reducing PLA2 expression,” *Laboratory Investigation*, vol. 100, no. 7, pp. 904–915, 2020.

[45] J. Jung, S. M. Lee, M. J. Lee et al., “Lipidomics reveals that acupuncture modulates the lipid metabolism and inflammatory interaction in a mouse model of depression,” *Brain, Behavior, and Immunity*, vol. 94, pp. 424–436, 2021.

[46] M. Ou, Q. Zhang, H. Zhao, and C. Shu, “Polyunsaturated fatty acid diet and upregulation of lipoxin A4 reduce the inflammatory response of preeclampsia,” *Journal of Proteome Research*, vol. 20, no. 1, pp. 357–368, 2021.

[47] M. Rauen, D. Hao, A. Müller, E. Mückter, L. C. Bollheimer, and M. Nourbakhsh, “Free fatty acid species differentially modulate the inflammatory gene response in primary human skeletal myoblasts,” *Biology*, vol. 10, no. 12, 2021.

[48] D. F. Romagnolo, M. G. Donovan, T. C. Doetschman, and O. I. Selmin, “N-6 linoleic acid induces epigenetics alterations associated with colonic inflammation and cancer,” *Nutrients*, vol. 11, no. 1, p. 171, 2019.

[49] D. R. Warner, J. B. Warner, J. E. Hardesty et al., “Decreased ω-6/ω-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injury,” *Journal of Lipid Research*, vol. 60, no. 12, pp. 2034–2049, 2019.

[50] N. Bar, T. Korem, O. Weissbrod et al., “A reference map of potential determinants for the human serum metabolome,” *Nature*, vol. 588, no. 7836, pp. 135–140, 2020.

[51] K. Bedard and K. H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” *Physiological Reviews*, vol. 87, no. 1, pp. 245–313, 2007.

[52] S. K. Shin, H. W. Cho, S. E. Song, and D. K. Song, “Catalase and nonalcoholic fatty liver disease,” *Pflügers Archiv*, vol. 470, no. 12, pp. 1721–1737, 2018.

[53] C. Ma, A. H. Kesarwala, T. Eggert et al., “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis,” *Nature*, vol. 531, no. 7593, pp. 253–257, 2016.

[54] X. Li, D. Wu, and Y. Tian, “Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/Nrf2/HO-1 pathway,” *Biochemical and Biophysical Research Communications*, vol. 502, no. 1, pp. 62–68, 2018.